A biopharmaceutical company focused on proof-of-concept trials of the clinical development process. [Read More]
A convertible security is a security that can be converted into another security. Convertible securities may be convertible bonds or preferred stocks that pay regular interest and can be converted into shares of common stock (sometimes conditioned on the stock price appreciating to a predetermined level).
Debt and Equity Opportunity
January 01, 0001
January 21, 2020
Open to Investors
Research & Development, Loan Repayment, General Working Capital, Marketing and Management Expenses, ABV-1701 Vitargus pilot production line
Howard Doong, M.D., Ph. D.
Formerly CAP-certified Laboratory Director of Taipei Veteran General Hospital Laboratory of Cancer Genomic Medicine, CEO of Frasergen Genomic Medicine Corp. and Vice President of TrimGen Corporation, a manufacturer of molecular diagnostic reagents and medical instruments. Formerly professor at University of Maryland and researcher at National Institutes of Health (NIH). Ph.D. from The University of Chicago, Department of Organismal Biology and Anatomy; and Department of Surgery. MD/Ph.D. Program, Harvard-MIT Division of Health
Sciences and Technology.*
Dr. T.S. Jiang
Chief Strategy Officer and Director
Currently Chairman of new drug development company BioLite, Inc. As President of PhytoHealth Corporation, led the team that developed and commercialized PG2 Lyo Injection, a new drug to treat cancer related fatigue. Previously director of Taiwan Bio Industry Organization.
Dr. Chi-Hsin Richard King
Chief Scientific Officer
Formerly SVP at pharmaceutical company TaiGen. Formerly Director at Medicinal Chemistry Department at drug discovery and manufacturing company Albany Molecular Research Inc., sold to the Carlyle Group for $1.5B in 2017.
Chairman and interim CFO
Director for new drug development company BioLite Incorporation, and an Executive Officer for Genepro Investment Company.
$7.00 per share